Making the mRNA in volume is the easy part. They can turn that around extremely quickly-- large prototype quantities in days, and begin ramping sharply in weeks.
The hard part is the formulation chemistry and microfluidics and nanoparticles, which don't change based upon variant mix.
Of course, the really hard part is approval, but we feel we understand influenza viruses and vaccines enough to have developed an expedited approval process each year. We should be able to do the same for COVID-19.
The hard part is the formulation chemistry and microfluidics and nanoparticles, which don't change based upon variant mix.
Of course, the really hard part is approval, but we feel we understand influenza viruses and vaccines enough to have developed an expedited approval process each year. We should be able to do the same for COVID-19.